Transaction DateRecipientSharesTypePriceValue
4th December 2020Bros. Advisors Lp Baker1,386,033Open or private sale$220.50$305,620,276.50
4th December 2020Bros. Advisors Lp Baker125,513Open or private sale$220.50$27,675,616.50
20th November 2020Jason Ehrlich981Open or private sale$138.56$135,927.36
20th November 2020Jason Ehrlich57Open or private sale$140.88$8,029.88
20th November 2020Jason Ehrlich2,134Open or private sale$139.39$297,453.99
20th November 2020Jason Ehrlich400Open or private sale$137.27$54,906.80
20th November 2020Jason Ehrlich2,614Open or private sale$139.96$365,865.90
20th November 2020Jason Ehrlich505Open or private sale$133.71$67,525.07
20th November 2020Jason Ehrlich259Open or private sale$134.72$34,892.22
20th November 2020Jason Ehrlich6,950Exercise of derivative$10.29$71,515.50
Kodiak Sciences
Kodiak Sciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.

Ticker: KOD
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1468748
Employees: 39
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $270 M (0%)
Marketable Securities, Current: $147 M (18%)
Assets, Current: $419 M (23%)
Property, Plant and Equipment, Net: $1 M (11%)
Other Assets, Noncurrent: $8 M (49%)
Assets: $429 M (19%)
Accounts Payable, Current: $7 M (168%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $19 M (60%)
Other Liabilities, Noncurrent: $276 Th (-6%)
Liabilities: $120 M (789%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $45 M (0%)
Additional Paid in Capital, Common Stock: $517 M (2%)
Retained Earnings (Accumulated Deficit): $209 M (31%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $594 Th (5840%)
Stockholders' Equity (Parent): $309 M (0%)
Liabilities and Equity: $429 M (19%)
Research and Development: $21 M (-49%)
General and Administrative Expenses: $6 M (-47%)
Operating Income/Loss: $27 M (-48%)